AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30832638 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 month text message intervention (DTEXT)
Number of subjects: 340
Study 29290208 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women aged 50-54.9 years
Number of subjects: 932
Study 29290208 — intervention group
Group type: COMPARATOR
Intervention: Women aged 60-64.9 years
Number of subjects: 932
Study 29290208 — intervention group
Group type: COMPARATOR
Intervention: Women aged ≥65 years
Number of subjects: 932
Study 26935065 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole-oxantel pamoate
Number of subjects: 405
Study 26935065 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole-ivermectin
Number of subjects: 405
Study 26935065 — intervention group
Group type: EXPERIMENTAL
Intervention: albendazole
Number of subjects: 405
Study 26935065 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole
Number of subjects: 405
Study 26935065 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 405
Study 24456057 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based balance intervention using a Nintendo Wii
Number of subjects: 0
Study 24456057 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy modalities
Number of subjects: 0
Study 24456057 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Virtual reality and Standard physical therapy)
Number of subjects: 0
Study 24456057 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii balance board game scores
Number of subjects: 0
Study 22689471 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mL FV-puree-based drink (FVPD)
Number of subjects: 24
Study 22689471 — intervention group
Group type: COMPARATOR
Intervention: Control (no FVPD)
Number of subjects: 24
Study 20009917 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 80
Study 20009917 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine
Number of subjects: 80
Study 17602081 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel
Number of subjects: 122
Study 17602081 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine
Number of subjects: 122
Study 16123718 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Number of subjects: 90
Study 16123718 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 90
Study 16123718 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 90
Study 11887168 — intervention group
Group type: EXPERIMENTAL
Intervention: Premenopausal women
Number of subjects: 69
Study 11887168 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women
Number of subjects: 69
Study 10609985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 15 mg/5 mL
Number of subjects: 12
Study 10609985 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 30 mg/5 mL
Number of subjects: 12
Study 10609985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10609985 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 8538895 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.5 mg/kg
Number of subjects: 60
Study 8538895 — intervention group
Group type: COMPARATOR
Intervention: Rectal midazolam 0.5 mg/kg
Number of subjects: 60
Study 8538895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both routes
Number of subjects: 60
Study 1650015 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 50 micrograms/m2
Number of subjects: 17
Study 1650015 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF 500 micrograms/m2
Number of subjects: 17
Study 1650015 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF during chemotherapy
Number of subjects: 17
Study 1650015 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy without GM-CSF
Number of subjects: 17
Study 6345596 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 20 mg/day, propranolol 40 mg/day)
Number of subjects: 29
Study 6345596 — intervention group
Group type: COMPARATOR
Intervention: Double regimen (chlorthalidone 25 mg/day, propranolol 103 mg/day)
Number of subjects: 29
Study 6345596 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple regimen (chlorthalidone 25 mg/day, oxdralazine 56 mg/day, propranolol 112 mg/day)
Number of subjects: 29
Study 6345596 — intervention group
Group type: COMPARATOR
Intervention: Double regimen (chlorthalidone 25 mg/day, propranolol 222 mg/day)
Number of subjects: 29
Study 29800637 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing caries with a flowable resin (SC)
Number of subjects: 28
Study 29800637 — intervention group
Group type: COMPARATOR
Intervention: Partial removal of caries followed by restoration (PRC)
Number of subjects: 28
Study 26258462 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshops on diet (4-5 sessions)
Number of subjects: 148
Study 26258462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no workshops)
Number of subjects: 148
Study 23203821 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐K (30 μg, 60 μg, 120 μg, or 240 μg)
Number of subjects: 28
Study 23203821 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 23203821 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐K
Number of subjects: 28
Study 21356025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetyl-pyridinium chloride mouth rinse
Number of subjects: 0
Study 21356025 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine and CPC (positive control)
Number of subjects: 0
Study 21356025 — intervention group
Group type: COMPARATOR
Intervention: Negative control (similar to the test product, without active ingredients)
Number of subjects: 0
Study 21356025 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival index
Number of subjects: 0
Study 21356025 — intervention group
Group type: EXPERIMENTAL
Intervention: Total colony forming units
Number of subjects: 0
Study 19506491 — intervention group
Group type: EXPERIMENTAL
Intervention: Jobskin pressure garments and Mepiform silicone sheeting
Number of subjects: 22
Study 19506491 — intervention group
Group type: COMPARATOR
Intervention: Jobskin pressure garments alone
Number of subjects: 22
Study 19506491 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure therapy (PT) group
Number of subjects: 22
Study 16790659 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of 1% preservative free 2‐chloroprocaine
Number of subjects: 45
Study 16790659 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of 1% preservative free 2‐chloroprocaine
Number of subjects: 45
Study 16790659 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of 1% preservative free 2‐chloroprocaine
Number of subjects: 45
Study 12734530 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling intervention
Number of subjects: 196
Study 12734530 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 196
Study 11051136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclopirox nail lacquer 8%
Number of subjects: 460
Study 9077496 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse Lewy body disease (DLBD)
Number of subjects: 0
Study 9077496 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer-type dementia (ATD)
Number of subjects: 0
Study 8418720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal nerve block with 0.25% bupivacaine, 0.75 mL/kg (group I)
Number of subjects: 82
Study 8418720 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal nerve block with 0.25% bupivacaine and 1:200,000 epinephrine, 0.75 mL/kg (group II)
Number of subjects: 82
Study 8418720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ilioinguinaliliohypogastric nerve block with epinephrine (group III)
Number of subjects: 82
Study 3511376 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid treatment (suspension, 400 mg, one and three hours after meals)
Number of subjects: 159
Study 3511376 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg, twice a day)
Number of subjects: 159
Study 3511376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 29796595 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed and suspended TRI with fasting
Number of subjects: 22
Study 29796595 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed and suspended TRI with oral intake of enteral nutrition
Number of subjects: 22
Study 29796595 — intervention group
Group type: COMPARATOR
Intervention: Whole-tablet TRI with fasting
Number of subjects: 22
Study 26205311 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic perconditioning (RIPerc)
Number of subjects: 201
Study 24921688 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 202
Study 22722651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (15-min infusion)
Number of subjects: 51
Study 22722651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (30-min infusion)
Number of subjects: 51
Study 22722651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lacosamide (60-min infusion)
Number of subjects: 51
Study 22722651 — intervention group
Group type: COMPARATOR
Intervention: Oral lacosamide (tablet)
Number of subjects: 51
Study 20542574 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on progress provided to clinicians and patients (n=408)
Number of subjects: 1308
Study 20542574 — intervention group
Group type: COMPARATOR
Intervention: Monitoring measures without feedback (n=439)
Number of subjects: 1308
Study 20542574 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (n=461)
Number of subjects: 1308
Study 18988473 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (DM) group
Number of subjects: 82
Study 18988473 — intervention group
Group type: COMPARATOR
Intervention: Control group (nondiabetic patients)
Number of subjects: 82
Study 19901570 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day Web-based treatment program
Number of subjects: 46
Study 15014430 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analysis at 5p15.3 using six markers
Number of subjects: 88
Study 15014430 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage analysis restricted to SLE families with 3 or more individuals with alleged RA
Number of subjects: 88
Study 11136208 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg diazepam up to three times daily
Number of subjects: 30
Study 11136208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9249647 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 inhibitor (celecoxib)
Number of subjects: 0
Study 9249647 — intervention group
Group type: COMPARATOR
Intervention: NSAID (not specified)
Number of subjects: 0
Study 7943770 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. DEX (2.5 micrograms/kg) and i.v. placebo (DexPla group)
Number of subjects: 192
Study 7943770 — intervention group
Group type: EXPERIMENTAL
Intervention: i.m. DEX (2.5 micrograms/kg) and i.v. fentanyl (FENT) (1.5 micrograms/kg) (DexFent group)
Number of subjects: 192
Study 7943770 — intervention group
Group type: COMPARATOR
Intervention: i.m. MID (0.08 mg/kg) and i.v. FENT (MidFent group)
Number of subjects: 192
Study 3107849 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM (standard doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Number of subjects: 50
Study 3107849 — intervention group
Group type: COMPARATOR
Intervention: Hi-FAM (high doses of 5-fluorouracil, adriamycin, and mitomycin-C)
Number of subjects: 50
Study 11908811 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulants
Number of subjects: 16
Study 11908811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30701377 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended self-management tools intervention
Number of subjects: 181
Study 30701377 — intervention group
Group type: COMPARATOR
Intervention: Brief Check Your Gambling intervention
Number of subjects: 181
Study 29508635 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine/liothyronine combination therapy
Number of subjects: 39
Study 29508635 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine alone
Number of subjects: 39
Study 26784863 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 327
Study 26784863 — intervention group
Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 327
Study 24184641 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous microwave diathermy
Number of subjects: 149
Study 24184641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed microwaves
Number of subjects: 149
Study 24184641 — intervention group
Group type: COMPARATOR
Intervention: Unplugged microwaves (Control)
Number of subjects: 149
Study 22305534 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with milk fat globule membrane (INPULSE), 200 mL daily for 4 months
Number of subjects: 182
Study 22305534 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with milk fat globule membrane (INPULSE)
Number of subjects: 182
Study 22305534 — intervention group
Group type: COMPARATOR
Intervention: Control formula (without milk fat globule membrane)
Number of subjects: 182
Study 20920265 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 565)
Number of subjects: 1126
Study 20920265 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 561)
Number of subjects: 1126
Study 17635246 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Number of subjects: 41
Study 15618073 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual chamber pacemaker with antitachyarrhythmia-pacing capability
Number of subjects: 105
Study 15618073 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-gathered diagnostic measures
Number of subjects: 105
Study 15618073 — intervention group
Group type: COMPARATOR
Intervention: Crossover design
Number of subjects: 105
Study 15618073 — intervention group
Group type: COMPARATOR
Intervention: Parallel design
Number of subjects: 105
Study 15618073 — intervention group
Group type: COMPARATOR
Intervention: Doubling the study period
Number of subjects: 105
Study 11999236 — intervention group
Group type: COMPARATOR
Intervention: VIC-I (1996-1998)
Number of subjects: 460
Study 11999236 — intervention group
Group type: EXPERIMENTAL
Intervention: VIC-II (1999-2000)
Number of subjects: 460
Study 10623333 — intervention group
Group type: EXPERIMENTAL
Intervention: NebuChamber spacer (AstraZeneca, Lund, Sweden)
Number of subjects: 13
Study 10623333 — intervention group
Group type: COMPARATOR
Intervention: Babyhaler spacer (GlaxoWellcome, Hertfordshire, UK)
Number of subjects: 13
Study 7869208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca gluconate-glycerophosphate preparation (group CaGP)
Number of subjects: 26
Study 7869208 — intervention group
Group type: COMPARATOR
Intervention: Ca phosphate (group CaTB)
Number of subjects: 26
Study 2374358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive macrofractional irradiation (25 Gr cumulative local dose)
Number of subjects: 451
Study 2374358 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (radiotherapy and surgery with local UHF hyperthermia)
Number of subjects: 451
Study 204971 — intervention group
Group type: EXPERIMENTAL
Intervention: INH 5 mg/kg body weight + RMP 10 mg/kg body weight + EMB 25 mg/kg body weight daily
Number of subjects: 75
Study 204971 — intervention group
Group type: COMPARATOR
Intervention: INH 15 mg/kg body weight + RMP 10 mg/kg body weight + EMB 40 mg/kg body weight, intermittent administration (2/7)
Number of subjects: 75
Study 31084557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Tri-S Bond Plus with Clearfil Majesty ES-2 composite (TS)
Number of subjects: 24
Study 31084557 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal in self-etch mode with Filtek Z350 XT composite (SB)
Number of subjects: 24
Study 31084557 — intervention group
Group type: COMPARATOR
Intervention: Plafique Bond with Plafique LX 5 composite (PB)
Number of subjects: 24
Study 28458128 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of safety signals during extinction
Number of subjects: 48
Study 28458128 — intervention group
Group type: COMPARATOR
Intervention: Absence of safety signals during extinction
Number of subjects: 48
Study 24696226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive motivational adherence counselling
Number of subjects: 297
Study 24696226 — intervention group
Group type: COMPARATOR
Intervention: Didactic counselling
Number of subjects: 297
Study 25122429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 1967
Study 22932864 — intervention group
Group type: EXPERIMENTAL
Intervention: Subperiosteal drain (SPD)
Number of subjects: 50
Study 22932864 — intervention group
Group type: COMPARATOR
Intervention: Subdural drain (SDD)
Number of subjects: 50
Study 19131370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100mg twice a day
Number of subjects: 26
Study 19131370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 17126073 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg daily)
Number of subjects: 40
Study 17126073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15314537 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided progressive resistance training
Number of subjects: 46
Study 15314537 — intervention group
Group type: COMPARATOR
Intervention: Active-assisted robot-aided exercises
Number of subjects: 46
Study 15314537 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-aided exercise training (all groups)
Number of subjects: 46
Study 15131468 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 297
Study 15131468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 11318908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (quEST intervention)
Number of subjects: 479
Study 9129604 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 min treadmill exercise test
Number of subjects: 24
Study 9129604 — intervention group
Group type: COMPARATOR
Intervention: Heel raising exercise
Number of subjects: 24
Study 7961258 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake increased by 50% with no change in physical activity (positive energy balance)
Number of subjects: 19
Study 7961258 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE increased by 50% by increasing physical activity, matched by a 50% increase in energy intake (energy balance at high energy flux)
Number of subjects: 19
Study 7961258 — intervention group
Group type: EXPERIMENTAL
Intervention: TEE increased by 50% by increasing physical activity with no change in energy intake (negative energy balance)
Number of subjects: 19
Study 7961258 — intervention group
Group type: COMPARATOR
Intervention: No change in energy intake or physical activity (energy balance at low energy flux)
Number of subjects: 19
Study 3599226 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 150 mg netilmicin sulfate 1 hour preoperatively
Number of subjects: 100
Study 3599226 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of 1.5 ml of 0.9% sodium chloride 1 hour preoperatively
Number of subjects: 100
Study 31920016 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zabofloxacin for the treatment of COPD exacerbations
Number of subjects: 0
Study 30497488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ojeok-san
Number of subjects: 60
Study 30497488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28494802 — intervention group
Group type: EXPERIMENTAL
Intervention: Active intervention (smartphone app with psychoeducational materials and exercises based on CBT for depression)
Number of subjects: 220
Study 28494802 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention (sham version of the app with similar structure of courses and exercises)
Number of subjects: 220
Study 28494802 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (access to the app after 6 weeks)
Number of subjects: 220
Study 26150070 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray (24IU)
Number of subjects: 21
Study 26150070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 23064993 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Arthroscopy (HA)
Number of subjects: 38
Study 23064993 — intervention group
Group type: COMPARATOR
Intervention: Surgical Hip Dislocation (SHD)
Number of subjects: 38
Study 21592309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg)
Number of subjects: 12
Study 21592309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18720130 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training for tendinopathy of the AT
Number of subjects: 116
Study 16689000 — intervention group
Group type: EXPERIMENTAL
Intervention: Salpingostomy combined with Bushen Huoxue Decoction (BHD), 1 dose every day starting from the 5th day of menstrual cycle for 14 days, with hydrotubation using Xiangdan Injection (XI) applied once in the next menstrual cycle after salpingostomy.
Number of subjects: 0
Study 16689000 — intervention group
Group type: COMPARATOR
Intervention: Salpingostomy alone with hydrotubation using Xiangdan Injection (XI).
Number of subjects: 0
Study 12712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and fentanyl (Group MF)
Number of subjects: 80
Study 12712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and fentanyl (Group PF)
Number of subjects: 80
Study 12712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and remifentanil (Group MR)
Number of subjects: 80
Study 12712779 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil (Group PR)
Number of subjects: 80
Study 12712779 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 80
Study 11178293 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive LIMA-to-LAD bypass
Number of subjects: 158
Study 8708654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin low dose (< 100 mg per day)
Number of subjects: 6171
Study 8708654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin medium dose (300 to 325 mg per day)
Number of subjects: 6171